## Letairis<sup>®</sup> Prescription and LEAP Patient Support Enrollment Form

				<del>.</del>		-PP-0.				
Please com	olete all fie	lds on this form to preven	t any delay	s in shipm	ent of Letairis	to your pati	ent and fax to 1-888	-882-4035.		
1 Patient I	nformatio	<b>n</b> (PLEASE PRINT)								
First Name: Middle Initial:				al:	Last Name:					
Address:					City:			State:	ZIP:	
Birthdate:	Gender: ☐ M ☐ F				Mobile Phone: Email:			•		
Alternate Contact Name:					Alternate Phone: Relationship:					
Patient Permission for Gilead to Provide Educational Information  I authorize Gilead Sciences, Inc., its affiliates, agents and contractors (collectively, "Gilead") to provide me with helpful tips about living with PAH, information about Gilead products and programs, and support for maintaining my prescribed treatment. I authorize my healthcare providers, pharmacies, health plans, or payers (my "healthcare organizations") to share personal and health information about me related to my Gilead PAH therapies ("my information") with Gilead (by signing Section 3 below) in order for Gilead to use it to communicate with me, including by e-mail, mail, or telephone (including voicemail and text messaging). Gilead may also use my information to learn how well Gilead programs are working. I understand that if I do not initial below, I will still be eligible for health plan benefits and treatment by my doctor will not change, but I will not receive the communications described above.										
Please initial here to confirm your enrollment										
Patient Written Permission to Share Protected Health Information										
I authorize my healthcare organizations to share my information with Gilead. I understand that once my information is shared with Gilead, my information may be protected by certain state privacy laws but not by federal health privacy laws, and may be redisclosed by Gilead. Gilead agrees to protect my information and to use and share it only for the reasons listed below. I understand that my pharmacy may receive compensation in connection with sharing my information with Gilead as allowed under this Authorization.  I authorize my healthcare organizations to share my information with Gilead, in order for Gilead to use and disclose my information for the following reasons: (1) to contact me or my healthcare organizations, or others I have identified, about my disease or treatment; (2) to confirm my health plan eligibility and benefits, identify other payers for my therapy, or determine whether I may be eligible for assistance programs; and (3) to communicate with me as described in Section 2 above, if selected.										
This Authorization will expire 10 years from the date signed below unless a shorter period is required by the law of my state of residence. I may also cancel my permission at any time by writing a letter to Gilead and faxing to 1-888-882-4035 or by calling 1-866-664-5327. If I do not sign this form, I understand my eligibility for health plan benefits and treatment by my doctor will not change. I am allowed a copy of this signed authorization.										
Patient or Patient Representative: X Patient or Patient Representative: X								Date:	/ /	
4 Specialty Pharmacy (LEAP WILL SEND PRESCRIPTION TO PATIENT'S IN-NETWORK PHARMACY)										
Select a preferred Certified Pharmacy:										
☐ Accredo ☐ CVS Caremark									Humana Specialty Pharmacy	
5 Dura suite			. waigreens P	nine	□ Acana	nealth Fhairna	СУ	OptumRx		
5 Prescrib First Name:	er informa	ation (Please Print)	Last Name:				State License #:			
Address:					City:			State:	ZIP:	
Phone:	one: Fax: ( ) -				NPI #:					
Office Contact (First and Last Name):										
6 Diagnos										
ICD-10 I27.0 Primary Pulmonary Hypertension ICD-10 I27.21 Secondary Pulmonary Arterial Hypertension										
☐ Idiopathic PAH☐ Heritable PAH☐					☐ Connective tissue disease ☐ Congenital heart disease with repaired shunts					
☐ Other (please specify): _										
Prescription  New York prescribers, please submit prescription on an original NY State prescription blank. For all other States, if not faxed or e-prescribed, prescribed, prescribers in all States must follow applicable State law. Prescribers and all female patients must be enrolled in the REMS program prior to initiating treatment.										
LETAIRIS: ☐ 5 mg tablets (30 tablets) PO QD Refills: Instructions:										
Ship to: ☐ Patient Home (address listed above) ☐ Prescriber Office (address listed above) ☐ Other (please indicate below)										
Name:				Address:						
City: State:					ZIP:			Phone: ( ) –		
By providing my signature, I authorize LEAP to act on my behalf for the limited purposes of transmitting this prescription to the pharmacy description of the pharmacy des									designated by the patient's benefit plan.	
REQUIRED FOR	Prescriber Signature ( <i>Dispense as Written</i> ):  NO STAMP ALLOWED X							Date:	/ /	
ALL PATIENTS (SIGN ONE)	Prescriber Signature (Substitution Allowed):  NO STAMP ALLOWED X							Date:	/ /	
		all patient insurance info	ormotion i	noluding	phormooy bo	actit cardo	(front and book) to	1 000 000	4025	

Please visit www.letairis.com/professional/enrollpatient or call 1-866-664-5327 for more information. Please click here for patient Medication Guide and Prescribing Information, including BOXED WARNING.

